MGMT and glioblastoma: Pharmacological inhibition of Connexin 43 or gap junction but also meclofenamate inhibition of intercellular cytosolic traffic via gap junctions reduced glioblastoma cell resistance to Temozolomide and Lomustine, independently of MGMT status [25–27].